Mind Medicine (MindMed) Inc (OTCMKTS:MMEDF) has been on an absolute tear of late. Due to its groundbreaking work in the psychedelic field, the company’s stock has gained more than 200% in the last 2 months!
Co-founder and Co-CEO JR Rahn is a former Silicon Valley tech executive who partnered with drug development veteran Stephen Hurst to form MindMed in 2019. JR has helped create a leading clinical drug development team with vast experience in psychedelics.
Recently I had the chance to meet with him and discuss the latest positive regulatory feedback. He also shared why he feels MindMed has the greatest toolset to capitalize on the next generation of psychedelic-inspired medicines…
For the full interview and my latest stock recommendations and analysis, sign up for the James West Letter here.